



Nippon India Nifty Pharma ETF

(An open ended scheme replicating/ tracking NIFTY Pharma Index)

Product label

| Product label | | |
|--|---|--|
| This product is suitable for investors who are seeking*: | Scheme Riskometer | Benchmark Riskometer |
| <ul style="list-style-type: none"> Long term capital growth Investment in equity and equity related securities and portfolios replicating the composition of Nifty Pharma Index, subject to tracking errors. <p>*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.</p> | <p>Nippon India Nifty Pharma ETF</p>  <p>The risk of the scheme is Very High</p> | <p>Nifty Pharma TRI</p>  <p>The risk of the benchmark is Very High</p> |

Contents

| | |
|--|--------|
| Why Equity ETF? | Page 2 |
| Strategies used through Index based Equity ETFs | Page 2 |
| Transaction Options available for investors | Page 2 |
| Creation Unit Size | Page 2 |
| Nippon India Nifty Pharma ETF - Investment Objective & Positioning | Page 3 |
| Benefits of Nippon India Nifty Pharma ETF | Page 3 |
| About Nifty Pharma Index | Page 3 |
| Current Valuations | Page 4 |
| Scheme Portfolio of Nippon India Nifty Pharma ETF | Page 4 |
| Scheme Features Nippon India Nifty Pharma ETF | Page 4 |

Nippon Life India Asset Management Limited (NAM India) is one of the largest asset managers with more than 29 years of experience in managing wealth of investors with a robust distribution network in India.

To cater to the increasing demand for passive management, we offer a variety of Exchange Traded Funds (ETFs) under "Nippon India ETFs". Currently, we offer eighteen equity ETF's – benchmarked against Nifty Bank TRI, Nifty 100 TRI, Nifty 50 TRI, Nifty Midcap 150 TRI, Nifty India Consumption TRI, Nifty Dividend Opportunities 50 TRI, Nifty 50 Value 20 TRI, Nifty Next 50 TRI, Nifty Infrastructure TRI, Nifty50 Shariah TRI, Nifty PSU bank TRI, Nifty CPSE TRI, Nifty IT TRI, Nifty Pharma TRI, Hang Seng TRI, BSE Sensex TRI, BSE Sensex Next 50 TRI & Nifty Auto TRI; Four debt ETFs – benchmarked against Nifty 8-13 yr G- Sec Index, Nifty SDL Apr 2026 Top 20 Equal Weight Index, Nifty 5 Yr Benchmark G-Sec Index & Liquid ETF in money market space and two commodity ETF's – based on domestic prices of Gold and Silver.

Why Equity ETF?

- ▶ **Ease of transaction** - Can be easily bought / sold like any other stock on the exchange through terminals spread across the country
- ▶ **Ease of Liquidity** - Can be bought / sold anytime during market hours (subject to availability of buyer/seller) at prices prevailing in the market. Thus, investor transacts at real-time prices
- ▶ **Low Cost** - Generally less expensive than investing in multiple individual securities.
- ▶ **Other Special Features**
 - Instant diversification through exposure to a large number of stocks by purchasing as low as 1 unit
 - Buying / selling at close to live price and not end-of-day, also ability to put limit orders
 - Authorised Participants/ Market Makers / Large investors can buy directly from the AMC at Live Prices in creation unit sizes[^]

Strategies used through Index based Equity ETFs

- ▶ **Liquidity Management** - ETFs can be used for a given percentage of each asset class to provide a liquidity buffer across the asset allocation
- ▶ **Portfolio Completion** - ETFs allow investors to gain exposure to an asset class that is under-represented in the asset allocation
- ▶ **Cash Equitization** - ETFs assist in remaining fully invested into equity as per the allocation model, while maintaining liquidity, thus minimizing the cash drag effect on the portfolio
- ▶ **Portfolio Transitions** - Since ETFs are passive funds, they may help to maintain market exposure while there are changes in sector/ stock allocations in a portfolio, hence avoids the risk of missing any market movement

Transaction Options available for investors

| Subscription | Process | Features |
|--|---|---|
| Through Stock Exchange | Online Terminal / Stock Broker | <ul style="list-style-type: none"> • Can trade as less as 1 Unit • Unit credit on T+1 • Transaction on Exchange traded price • No paperwork • Transaction on order matching and availability of quotes |
| Through AMC (Authorized Participants/ Market Makers & Large Investors) | Transaction form with requisite documents | <ul style="list-style-type: none"> • Can transact in multiples of creation unit size[^] • Transaction in exchange of Portfolio deposit & Cash Component |
| Redemption | Process | Features |
| Through Stock Exchange | Online terminal / Stock Broker | <ul style="list-style-type: none"> • Can trade as less as 1 Unit • Amount credited T+1 |
| Through AMC (Authorized Participants/ Market Makers & Large Investors) | Redemption Request | <ul style="list-style-type: none"> • Can trade in multiples of creation unit size[^] • Transaction in exchange of Portfolio deposit & Cash Component |

Creation Unit Size

Creation Unit size is the minimum denomination of unit that can be directly purchased/redeemed from AMC

| Tradable Unit | Composition | Creation Unit Size [^] | NAV Value (Rs.)* | Approx. Basket Value (Rs.)* |
|--------------------------------------|-------------------------------|---|------------------|-----------------------------|
| 1 Unit Nippon India Nifty Pharma ETF | ~1/1000 of Nifty Pharma Index | 75,000 units of Nippon India Nifty Pharma ETF | 20.2317 | 15,17,378 |

*Data as of 28th February, 2025 taken as reference value

Nippon India Nifty Pharma ETF

Investment Objective Nippon India Nifty Pharma ETF

The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the Nifty Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.

Positioning – Nippon India Nifty Pharma ETF

- Nippon India Nifty Pharma ETF is an Exchange Traded Fund (ETF) which is listed on NSE and investing in stocks of Nifty Pharma Index in the same proportion as the underlying Index.
- Nippon India Nifty Pharma ETF is a low cost product in terms of total expense ratio
- It aims to provide investors who would like to participate in the India growth story by passively investing in sector based portfolio of well known companies as represented by Nifty Pharma Index.

Benefits of Nippon India Nifty Pharma ETF

- **Liquidity:** Apart from being readily available for trade on the recognized stock exchanges, ETF units can also be bought in creation units size[^] by large investors directly from the asset management company.
- **Less of Ambiguity:** The ETF's investment strategy & stock selection is clearly defined, holding stocks as per the underlying Index in the same weightages.
- **Transparency:** The index constituents are available in the public domain on a daily basis by NSE
- **Diversification:** Buying a single unit currently offers diversification of 20 stocks in the Pharmaceuticals sector and elimination of non-systematic risks like stock picking and portfolio manager selection by investing in the stock basket via Nippon India Nifty Pharma ETF.

Source: NSE & NSE Indices Ltd.

About Nifty Pharma Index

Overview

The Nifty Pharma Index is designed to reflect the behavior and performance of the companies that are engaged into manufacturing of pharmaceuticals and biotechnology companies.

Eligibility criteria for stock selection:

- Companies should form part of NIFTY 500 at the time of review.
- Minimum number of stocks within the index should be 10.
- In case, the number of eligible stocks within Nifty 500 falls below 10, then deficit number of stocks shall be selected from the universe of stocks ranked within top 800 based on both average daily turnover and average daily full market capitalisation based on previous six months period data used for index rebalancing of Nifty 500.
In case, the number of eligible stocks in the universe is still less than 10, then the deficit number of stocks shall be selected from the universe of stocks ranked within top 1000, top 1100, top 1200 and so on, based on both average daily turnover and average daily full market capitalization based on previous six months period data, until at least 10 eligible stocks are obtained. If the number of eligible stocks is still less than 10, then the index may have less than 10 constituents.
- Companies should form part of the Pharmaceuticals sector.
- The companies are sorted in the descending order of the Free-Float Market capitalization (FF MCap) and final selection of companies shall be made based on six-month average FF MCap that are available for trading in NSE Futures & Options (F&O). In case if the stocks selected are less than 20 then the deficit number of stocks are selected based on six-month average FF mcap.
- Stocks that are available for trading in F&O segment are compulsorily included in the index and will replace the smallest index constituent which are not available for trading in F&O segment subject to minimum of 20 stocks in index.
- In case all the stocks within the index are available for F&O trading and there is non-member eligible F&O stock, such stock will be included in the index only if its six-months average FF MCap is atleast 1.5 times the six-months average FF MCap of smallest index constituent.
- Non-member eligible stocks which are not available for trading for F&O segment will be included if its six-months average FF MCap is atleast 1.5 times the six-months average FF MCap of smallest index constituent which is not available for trading in F&O segment.

Index Re-Balancing:

The index is re-balanced on a semi-annual basis effective from the last trading day of March and September.

Source: NSE Indices Ltd.

Note: The performance of the scheme shall be benchmarked to the Total Return (TRI) variant of the Index chosen as a benchmark.

Current Valuations - Nifty Pharma Index

The P/E, P/B and dividend yield of Nifty Pharma Index are as follows

| Nifty Pharma Index Valuations | | | | |
|-------------------------------|-------------|---------------------|---------------------|--------------------|
| Date | Index Level | Price Earning (P/E) | Price to Book (P/B) | Dividend Yield (%) |
| 28-Feb-25 | 19813.5 | 29.95 | 4.84 | 0.7 |
| 31-Mar-23 | 12017.05 | 31.55 | 4.27 | 1.10 |
| 31-Mar-22 | 13584.10 | 33.00 | 4.85 | 0.68 |
| 31-Mar-21 | 12272.60 | 32.34 | 5.05 | 0.48 |

Note: The historical index values of the index are available on www.nseindia.com. Past performance may or may not be sustained in future. Investors are advised to consult their financial advisor before making any investment.

Scheme Portfolio of Nippon India Nifty Pharma ETF as on 28th February, 2025

| Sr. No. | Stock Name | Weightage (%) | Sr. No. | Stock Name | Weightage (%) |
|--------------|---------------------------------------|---------------|---------|--|----------------|
| 1 | Sun Pharmaceutical Industries Limited | 24.69% | 12 | Glenmark Pharmaceuticals Limited | 2.76% |
| 2 | Cipla Limited | 11.11% | 13 | IPCA Laboratories Limited | 2.64% |
| 3 | Divi's Laboratories Limited | 9.99% | 14 | Abbott India Limited | 2.27% |
| 4 | Dr. Reddy's Laboratories Limited | 9.77% | 15 | Biocon Limited | 1.95% |
| 5 | Lupin Limited | 6.59% | 16 | Gland Pharma Limited | 1.77% |
| 6 | Aurobindo Pharma Limited | 4.24% | 17 | JB Chemicals & Pharmaceuticals Limited | 1.69% |
| 7 | Torrent Pharmaceuticals Limited | 3.97% | 18 | Ajanta Pharma Limited | 1.50% |
| 8 | Alkem Laboratories Limited | 3.54% | 19 | Natco Pharma Limited | 0.99% |
| 9 | Mankind Pharma Limited | 3.41% | 20 | Granules India Limited | 0.96% |
| 10 | Zydus Lifesciences Limited | 3.14% | 21 | Cash & Other Receivables | 0.04% |
| 11 | Laurus Labs Limited | 2.98% | | | |
| Total | | | | | 100.00% |

Note: The stocks mentioned form a part of the portfolio of the scheme and may or may not form a part of the portfolio in future. Please read Scheme Information Document carefully for more details and risk factors

Scheme Performance Nippon India Nifty Pharma ETF as on 28th February, 2025

| Fund / Benchmark (Value of ₹10,000 invested) | 1 Year | | 3 Years | | 5 Years | | Since Inception | |
|--|-------------------------------------|-------------|-------------|-------------|-------------|-------------|-----------------|-------------|
| | Amount in ₹ | Returns (%) | Amount in ₹ | Returns (%) | Amount in ₹ | Returns (%) | Amount in ₹ | Returns (%) |
| NAV as on February 28, 2025: ₹20.2317 | | | | | | | | |
| Nippon India Nifty Pharma ETF | Inception Date : Jul 2, 2021 | | | | | | | |
| Nippon India Nifty Pharma ETF | 10,466 | 4.66 | 15,568 | 15.88 | NA | NA | 13,914 | 9.44 |
| B:Nifty Pharma TRI | 10,496 | 4.96 | 15,681 | 16.16 | NA | NA | 14,042 | 9.71 |
| AB:Nifty 50 TRI | 10,189 | 1.89 | 13,652 | 10.92 | NA | NA | 14,683 | 11.06 |
| Fund Manager : Himanshu Mange (Since Dec 2023 till 31st Jan 2025), Jitendra Tolani (w.e.f Feb 01, 2025) | | | | | | | | |

Performance as on 28th February, 2025

B: Benchmark, AB: Additional Benchmark, TRI: Total Return Index

TRI - Total Returns Index reflects the returns on the index arising from (a) constituent stock price movements and (b) dividend receipts from constituent index stocks, thereby showing a true picture of returns.

For Exchange Traded Funds of Nippon India Mutual Fund, performance is provided at Scheme level using IDCW Reinvestment NAV's, since there are no separate plan/option under such Schemes.

Period for which scheme's performance has been provided is computed basis last day of the month-end preceding the date of advertisement.

Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investment. Performance of the schemes (wherever provided) are calculated basis CAGR for the past 1 year, 3 years, 5 years and since inception. IDCWs (if any) are assumed to be reinvested at the prevailing NAV. Performance of the scheme would be Net of Dividend distribution tax, if any. Face value of scheme is Rs.10/- per unit. In case, the start/end date of the concerned period is non-business day (NBD), the NAV of the previous date is considered for computation of returns.

Finance Act 2020 has abolished dividend distribution tax on IDCW declared and paid by Mutual Fund scheme. W.e.f. 01.04.2020 IDCW received from Mutual fund scheme is taxable in the hands of investor and mutual fund scheme is required to withhold tax on IDCW as per applicable rate.

Performance of other open ended schemes managed by the same fund manager as on 28th February, 2025

| Scheme Name/s | CAGR % | | | | | | | | |
|--|---------------|-------------|-----------|----------------|-------------|-----------|----------------|-------------|-----------|
| | 1 Year Return | | | 3 Years Return | | | 5 Years Return | | |
| | Regular Plan | Direct Plan | Benchmark | Regular Plan | Direct Plan | Benchmark | Regular Plan | Direct Plan | Benchmark |
| TOP 3 | | | | | | | | | |
| Nippon India Silver ETF Fund of Fund# | 31.61 | -- | 34.82 | 11.09 | -- | 12.52 | NA | -- | NA |
| Nippon India Nifty Bank Index Fund# | 4.73 | 5.34 | 5.76 | NA | NA | NA | NA | NA | NA |
| Nippon India ETF Nifty India Consumption* | 4.23 | -- | 4.63 | 15.14 | -- | 15.58 | 16.64 | -- | 17.13 |
| Bottom 3 | | | | | | | | | |
| Nippon India Nifty Alpha Low Volatility 30 Index Fund# | -7.70 | -7.22 | -6.60 | NA | NA | NA | NA | NA | NA |
| Nippon India ETF Nifty 50 Shariah BeES* | -7.81 | -- | -6.71 | 3.48 | -- | 4.56 | 13.66 | -- | 14.92 |
| Nippon India ETF Nifty PSU Bank BeES* | -18.23 | -- | -17.85 | 29.29 | -- | 30.03 | 24.02 | -- | 24.76 |

Nippon India Silver ETF Fund of Fund has not completed 5 years, the performance details of 1 & 3 years are provided herein. Nippon India Nifty Bank Index Fund & Nippon India Nifty Alpha Low Volatility 30 Index Fund have not completed 3 & 5 years, the performance details of 1 years are provided herein.

Mr. Jitendra Tolani has been managing Nippon India Silver ETF Fund of Fund since Feb 2025
 Mr. Jitendra Tolani has been managing Nippon India Nifty Bank Index Fund since Feb 2025
 Mr. Jitendra Tolani has been managing Nippon India ETF Nifty India Consumption since Feb 2025
 Mr. Jitendra Tolani has been managing Nippon India Nifty Alpha Low Volatility 30 Index Fund since Feb 2025
 Mr. Jitendra Tolani has been managing Nippon India ETF Nifty 50 Shariah BeES since Feb 2025
 Mr. Jitendra Tolani has been managing Nippon India ETF Nifty PSU Bank BeES since Feb 2025

Note:

- Mr. Jitendra Tolani manages 19 open-ended schemes of Nippon India Mutual Fund.
- In case the number of schemes managed by a fund manager is more than six, in the performance data of other schemes, the top 3 and bottom 3 schemes managed by fund manager has been provided herein are on the basis of 1 Year CAGR returns
- Period for which scheme's performance has been provided is computed basis last day of the month-end preceding the date of advertisement
- Different schemes shall have a different expense structure.

#The performance details provided herein are of Growth plan.
 *The Scheme does not offer any Plans/Options. The performance details are provided at Scheme level using IDCW Reinvestment NAV's.

Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other Investment. IDCWs (if any) are assumed to be reinvested at the prevailing NAV. Performance of the scheme would be Net of Dividend distribution tax, if any. Face value of Nippon India ETF Nifty PSU Bank BeES is Re.1/- per unit. Face Value of other schemes is Rs.10/- per unit. In case, the start/end date of the concerned period is non-business day (NBD), the NAV of the previous date is considered for computation of returns.

Finance Act 2020 has abolished dividend distribution tax on IDCW declared and paid by Mutual Fund scheme. W.e.f. 01.04.2020 IDCW received from Mutual fund scheme is taxable in the hands of investor and mutual fund scheme is required to withhold tax on IDCW as per applicable rate.

Scheme Features of Nippon India Nifty Pharma ETF

| | |
|------------------------------------|---|
| Nature of Scheme | An open ended scheme replicating/ tracking NIFTY Pharma Index |
| Benchmark | Nifty Pharma TRI |
| Fund Manager | Jitendra Tolani (w.e.f Feb 01, 2025) |
| Inception date | 2nd July 2021 |
| Total Expense Ratio | 0.21% (as on 28th February, 2025) |
| Rule of 20-25 | Rule of a minimum of 20 investors and no single investor accounting for more than 25% of the corpus of the Scheme does not apply to ETFs |
| Asset Allocation | Securities constituting Nifty Pharma Index : 95%-100% Money Market Instruments including Tri-party Repo on government securities or T-bills, cash & cash equivalents or Liquid Schemes* : 0%-5% *The Fund Manager may invest in Liquid Scheme of Nippon India Mutual Fund and other schemes of a mutual fund registered with SEBI, that invest predominantly in the money market securities. Investors are requested to refer SID for more details. |
| Transparency/NAV Disclosure | Nippon India Mutual Fund shall declare the Net asset value of the scheme on every business day on AMFI's website www.amfiindia.com by 11:00 p.m. on the day of declaration of the NAV and also on mf.nipponindiaim.com |
| Value of Unit | The value of each unit of the Scheme would be approximately equal to 1/1000th of the value of Nifty Pharma Index |
| Load Structure | Exit Load : Not Applicable |
| Minimum Application Amount | The minimum number of Units that can be bought or sold on the exchange is 1 (one) unit and in multiples of 1 unit. Directly from AMC: Allowed to Authorized Participants/ Market Makers & Large Investors in form of creation unit size^ of 75,000 units. |
| Dematerialization | Dematerialization: Units of the scheme will be available in Dematerialized (electronic) form only |

| | |
|------------|------------|
| NSE Symbol | PHARMABEES |
|------------|------------|

As w.e.f May 1, 2023, the execution value for large investors must be greater than Rs.25 crores (except for Schemes managed by Employee Provident Fund Organisation (EPFO), India and Recognized Provident Funds, Approved Gratuity Funds and Approved Superannuation Funds under Income Tax Act, 1961)

Product Label

| Scheme Name | This Product is suitable for Investors who are Seeking* | Scheme Riskmeter | Benchmark Riskmeter |
|---|--|---|--|
| <p>Nippon India Silver ETF Fund of Fund (An Open Ended Fund of Fund scheme investing in units of Nippon India Silver ETF.)</p> <p>Benchmark : Domestic Price of Silver (based on LBMA Silver daily spot fixing price)</p> | <ul style="list-style-type: none"> Long term capital growth Returns that are commensurate with the performance of Nippon India Silver ETF through investment in units of Nippon India Silver ETF | <p>The risk of the scheme is Very High</p> | <p>The risk of the benchmark is Very High</p> |
| <p>Nippon India Nifty Bank Index Fund (An open ended scheme replicating/tracking Nifty Bank Index)</p> <p>Benchmark : Nifty Bank TRI</p> | <ul style="list-style-type: none"> Long term capital growth Investment in equity and equity related securities and portfolio replicating the composition of the Nifty Bank Index, subject to tracking errors. | <p>The risk of the scheme is Very High</p> | <p>The risk of the benchmark is Very High</p> |
| <p>Nippon India ETF Nifty India Consumption (An Open Ended Index Exchange Traded Fund.)</p> <p>Benchmark : Nifty India Consumption TRI</p> | <ul style="list-style-type: none"> Long term capital growth Investment in equity and equity related securities and portfolios replicating the composition of Nifty India Consumption Index, subject to tracking errors | <p>The risk of the scheme is Very High</p> | <p>The risk of the benchmark is Very High</p> |
| <p>Nippon India Nifty Alpha Low Volatility 30 Index Fund (An open ended scheme replicating/tracking Nifty Alpha Low Volatility 30 Index.)</p> <p>Benchmark : Nifty Alpha Low Volatility 30 TRI</p> | <ul style="list-style-type: none"> Long term capital growth Investment in equity and equity related securities and portfolio replicating the composition of the Nifty Alpha Low Volatility 30 Index, subject to tracking errors. | <p>The risk of the scheme is Very High</p> | <p>The risk of the benchmark is Very High</p> |
| <p>Nippon India ETF Nifty 50 Shariah BeES (The fund employs a passive investment approach designed to track the performance of Nifty50 Shariah TRI. The fund seeks to achieve this goal by investing in securities constituting the Nifty50 Shariah Index in same proportion as in the Index.)</p> <p>Benchmark : Nifty50 Shariah TRI</p> | <ul style="list-style-type: none"> Long-term capital appreciation Investment in Securities covered by Nifty50 Shariah Index | <p>The risk of the scheme is Very High</p> | <p>The risk of the benchmark is Very High</p> |
| <p>Nippon India ETF Nifty PSU Bank BeES (An open ended index scheme, listed on the Exchange in the form of an Exchange Traded Fund (ETF) tracking the Nifty PSU Bank Index.)</p> <p>Benchmark : Nifty PSU Bank TRI</p> | <ul style="list-style-type: none"> Long-term capital appreciation Investment in Securities covered by Nifty PSU Bank Index | <p>The risk of the scheme is Very High</p> | <p>The risk of the benchmark is Very High</p> |

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Risk Factors:

The NAV of the Scheme may be affected, inter alia, by changes in the market conditions, interest rates, trading volumes, settlement periods and transfer procedures. The NAV may also be subjected to risk associated with tracking error, investment in derivatives or script lending as may be permissible by the Scheme Information Document. Past performance may or may not be sustained in future.

NSE Disclaimer:

It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Scheme Information Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Scheme Information Document. The investors are advised to refer to the Scheme Information Document for the full text of the Disclaimer Clause of NSE.

Disclaimers:

• The information herein is meant only for general reading purposes and the views being expressed only constitute opinions and therefore cannot be considered as guidelines, recommendations or as a professional guide for the readers. Certain factual and statistical information (historical) pertaining to Industry and markets have been obtained from independent third-party sources, which are deemed to be reliable. It may be noted that since Nippon Life India Asset Management Limited (NAM India) has not independently verified the accuracy or authenticity of such information or data, or for that matter the reasonableness of the assumptions upon which such data and information has been processed or arrived at; NAM India does not in any manner assures the accuracy or authenticity of such data and information. Some of the statements & assertions contained in these materials may reflect NAM India's views or opinions, which in turn may have been formed on the basis of such data or information.

• Before making any investments, the readers are advised to seek independent professional advice, verify the contents in order to arrive at an informed investment decision. None of the Sponsor, the Investment Manager, the Trustee, their respective directors, employees, associates or representatives shall be liable in any way for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including on account of lost profits arising from the information contained in this material.



Mutual Fund investments are subject to market risks, read all scheme related documents carefully.